Dr. Ian Denison Schnadig, MD

Dr. Schnadig practices at Compass Oncology in Portland, Oregon.

Dr. Schnadig's NPI, 1467664839, was assigned on May 5, 2007. Dr. Schnadig graduated from Rush Medical College of Rush University in 2002. Dr. Schnadig holds Oregon license MD150796.

Dr. Schnadig's primary practice is Compass Oncology, at 12123 Sw 69th Ave, Portland, OR 97223 in Washington County. The practice phone is (360) 597-1300.

Dr. Schnadig's primary practice is Compass Oncology in Portland, Oregon. Dr. Schnadig is also affiliated with Providence St. Vincent Medical Center. The medical group on file is Compass Oncology. Dmand AI also links Dr. Schnadig to 2 more hospitals, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schnadig practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Schnadig's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Schnadig is licensed in Oregon.

CMS data shows 76,863 Medicare services from Dr. Schnadig across 52 procedure codes in 2024, for 442 Medicare patients. Medicare paid $692,055 for them. Every service was in an office.

CMS counts 442 Medicare patients who saw Dr. Schnadig in 2024. The largest group is 65 to 74, with 198 patients. 69% of them have high blood pressure, and 64% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schnadig's median patient age at 72, with 45% women.

In 2024, Dr. Schnadig wrote 1,895 Medicare Part D claims for 228 patients. 84% of them were for generic drugs. CMS names the drug for 1,658 of them, across 31 drugs with 11 or more claims each, at $3,655,466 in total drug cost. In 2023, CMS named 1,294 claims across 29 drugs.

Dr. Schnadig accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schnadig as offering telehealth.

Dmand AI links 19 papers to Dr. Schnadig, published from 2012 to 2020. 2015 was the busiest year, with 5. The most frequent topics are Nausea, Spiro Compounds and Vomiting. Dr. Schnadig has published most often in Clin Genitourin Cancer. Dr. Schnadig's most frequent co-authors are Lee S. Schwartzberg, MD, Rudolph M. Navari, MD and Mark D. Kochenderfer, MD.

Dmand AI links Dr. Schnadig to 3 clinical trials. Conditions studied include Carcinoma, Transitional Cell, Neoplasm Metastasis and Neoplastic Processes. Open Payments lists research payments to Dr. Schnadig that name 1 trial.

CMS Open Payments shows 14 general payments to Dr. Schnadig from 7 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 70% of the total. Sanofi and Genzyme US Companies paid the most, $6,400. It also lists 1 research payment totaling $73 in 2019, naming 1 clinical trial.

Dr. Schnadig graduated from Rush Medical College of Rush University in 2002.